



## Emerging Paradigms in Severe Asthma Management: Integrating Technology and Personalized Treatment

Guest Editors:

**Dr. Rudolfo Álvarez-Sala-Walther**

Respiratory Medicine Service,  
Hospital Universitario La Paz,  
Universidad Autónoma de  
Madrid, IdiPAZ, Madrid, Spain

**Dr. Santiago Quirce**

Department of Allergy, Hospital  
Universitario La Paz, Institute for  
Health Research (IdiPAZ), CIBER  
of Respiratory Diseases  
(CIBERES), Madrid, Spain

Deadline for manuscript  
submissions:

**30 October 2024**

### Message from the Guest Editors

Severe uncontrolled asthma is defined as asthma that remains insufficiently controlled despite receiving intensive asthma treatment after asthma diagnosis has been confirmed and considering comorbidities that may mimic asthma. The prevalence of severe uncontrolled asthma is estimated at 5% of all asthma cases. In this context, biological drugs have emerged as a promising option to address severe asthma. These medications target the specific immune system mechanisms involved in bronchial inflammation, providing a more precise and effective approach. By targeting specific cytokines and immune cells, biologics can help reduce symptoms, improve lung function, and decrease the frequency of exacerbations in patients with severe asthma.

A key theme of this Special Issue is the role of technology, particularly artificial intelligence (AI), telemedicine, big data, and bioinformatics, in transforming asthma care. The integration of these technologies is reshaping the management of asthma, enhancing diagnostic precision, personalizing treatment plans, and improving patient outcomes.





an Open Access Journal by MDPI

## Editors-in-Chief

**Prof. Dr. Emmanuel Andrès**

Internal Medicine Department,  
University Hospital Strasbourg,  
67000 Strasbourg, France

**Prof. Dr. Kent Doi**

Department of Emergency and  
Critical Care Medicine, University  
of Tokyo, Tokyo 113-8655, Japan

## Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Medicine, General & Internal*) / CiteScore - Q1 (*General Medicine*)

## Contact Us

*Journal of Clinical Medicine* Editorial  
Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/jcm](http://mdpi.com/journal/jcm)  
[jcm@mdpi.com](mailto:jcm@mdpi.com)  
[X@JCM\\_MDPI](https://twitter.com/JCM_MDPI)